Soleno Therapeutics, Inc. announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). The randomized withdrawal period of Study C602 is a multi-center, randomized, double-blind, placebo-controlled study of DCCR in approximately 80 patients with PWS at 17 sites in the U.S. and 5 sites in the U.K. This randomized withdrawal period consists only of patients currently enrolled in Study C602 and will not enroll any new patients. Upon Institutional Review Board/Ethics approvals at their respective sites, patients who consent to participate in the randomized withdrawal period, will be randomized to receive DCCR or placebo for a period of four months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.02 USD | -2.47% | +0.85% | +11.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.85% | 1.64B | |
+17.73% | 124B | |
+16.88% | 111B | |
-9.04% | 23.17B | |
+5.47% | 22.94B | |
-38.15% | 17.42B | |
-7.75% | 17.42B | |
-15.20% | 16.9B | |
+3.42% | 13.71B | |
+29.63% | 11.82B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome